High-resolution analysis of protein dynamics for epitope mapping, conformational stability, and localization of binding interfaces.
Hydrogen-deuterium exchange mass spectrometry delivers residue-level insight into protein conformation, dynamics, and interaction surfaces — essential data for biosimilarity assessments, structural elucidation, and comparability studies.
Precisely localize antibody-antigen binding interfaces at peptide-level resolution. Define conformational and linear epitopes to inform rational design.
Monitor higher-order structure changes across formulations, stress conditions, and manufacturing processes with quantitative deuterium uptake profiles.
Generate the higher-order structure comparability data required for biosimilar regulatory submissions with validated, reproducible methods.
Characterize protein-protein, protein-ligand, and multi-component binding surfaces to support mechanism-of-action studies and formulation development.
Detect higher-order structure changes across manufacturing process changes, site transfers, and lot-to-lot variation with quantitative HDX-MS comparisons.
Evaluate the structural impact of thermal, oxidative, and pH stress on higher-order structure to identify degradation-sensitive regions and inform stability programs.
Screen formulation candidates by monitoring HOS changes across buffer, excipient, and concentration conditions to select optimal formulations early.
Map conformational changes upon ligand binding, receptor engagement, or allosteric modulation to support MoA characterization and rational drug design.
We combine the scientific rigor of a large CRO with the speed and flexibility of a dedicated specialist lab. Here's what sets us apart.
HDX-MS studies operate in the hundreds-of-micrograms range. We optimize protocols to minimize sample consumption, making structural data accessible even when material is limited.
Work directly with the scientists running your experiments. No project managers in between — fast decisions, fast turnaround, and full transparency.
Submission-ready data packages for IND, BLA, IMPD, and biosimilar filings. Full method documentation, validated workflows, and audit-ready records.
Five mass spectrometers across Thermo, Waters, Bruker, and SCIEX platforms. Choose the right instrument for your specific analytical challenge.
Every deliverable is designed for regulatory submission or peer-reviewed publication — clear figures, complete methods, and rigorous statistical analysis.
No rigid service menus. We design custom protocols tailored to your molecule, your questions, and your regulatory pathway.
From monoclonal antibodies and ADCs to bispecifics, fusion proteins, nanobodies, and gene therapy vectors — we've characterized them all.
Projects start immediately upon receipt. No queue, no waiting. Most HDX-MS studies completed and reported within weeks, not months.
When higher-order structure data drives your IND, BLA, IMPD, or biosimilar filing strategy, you need a partner with deep expertise in mass spectrometry-based structural analysis. Baselayer delivers publication-quality data with the rigor and documentation that regulatory agencies and development teams demand.
Our team has hands-on experience with the full spectrum of biologic drug formats, from conventional mAbs through next-generation modalities.
From primary structure confirmation to higher-order structural analysis, our integrated platform covers the full spectrum of mass spectrometry-based characterization.

Confirmation of primary sequence and comprehensive localization of post-translational modifications including oxidation, deamidation, and glycosylation sites.

High-resolution analysis of protein dynamics for epitope mapping, conformational stability, and localization of binding interfaces across therapeutic modalities.

Detailed glycosylation site identification, glycan structure characterization, and quantitative profiling to support lot-to-lot consistency and CQA monitoring.

Top-down and bottom-up mass spectrometry approaches for intact mass analysis, subunit characterization, and deep protein identification across complex matrices.

Proprietary HDX-MS workflow designed to resolve epitope diversity within polyclonal antibody responses — critical for vaccine and immunogenicity programs.
Our scientists will help design the right analytical strategy for your molecule and regulatory pathway.
Discuss Your ProjectFive high-resolution mass spectrometers across four vendor platforms give us the flexibility to match the right instrument to your analytical challenge.
High-resolution Orbitrap for intact mass, peptide mapping, and multi-attribute monitoring.
Tribrid platform with advanced fragmentation for deep sequence characterization and PTM analysis.
Q-TOF with ion mobility separation for high-resolution HDX-MS and conformational analysis.
Trapped ion mobility platform for enhanced peptide coverage and isomer resolution.
High-speed accurate mass instrument for quantitative workflows and broad peptide identification.
Our team combines deep expertise in mass spectrometry, structural biology, and biopharmaceutical development. Every project is led by experienced scientists who understand the science and the regulatory context.
Chief Executive Officer
Specialist in HDX-MS and structural mass spectrometry with extensive experience in biologics characterization for pharma and biotech development programs.
Chief Scientist
Expert in structural mass spectrometry and protein biophysics with deep experience designing and executing HDX-MS studies for biopharma clients.
Chief Engineer
Leads instrument development and laboratory infrastructure. Specialist in mass spectrometry systems integration, HDX automation, and analytical workflow engineering.
Tell us about your molecule, your timeline, and your regulatory context. We'll design a characterization strategy that delivers the data you need.